1. Tvardi's shares dropped over 80% after Phase 2 trial disappointment. 2. Preliminary data from REVERT trial shows study goals were not met. 3. Investors experiencing losses encouraged to contact legal counsel. 4. Faruqi & Faruqi investigating potential claims against Tvardi.
FAQ
Why Very Bearish?
The dramatic drop in share price indicates significant investor loss and confidence erosion, drawing historical parallels to similar cases where clinical failures have led to substantial stock declines.
How important is it?
The article directly discusses severe stock declines and potential legal ramifications for Tvardi, indicating significant market impact.
Why Short Term?
The immediate aftermath of the trial results will likely affect stock price volatility, but long-term recovery depends on future clinical successes or strategic pivots.
Faruqi & Faruqi Investigates Claims for Investors of Tvardi Therapeutics
On October 13, 2025, shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) experienced a dramatic fall of over 80% following the release of disappointing preliminary data from its Phase 2 REVERT clinical trial. This investigation, led by Faruqi & Faruqi, LLP, seeks to address concerns raised by investors impacted by this decline.
Significant Losses Trigger Legal Inquiry
Faruqi & Faruqi, a prominent national securities law firm, initiated an investigation into potential claims on behalf of investors who suffered major losses in Tvardi stock or options. The firm encourages affected investors to contact their Securities Litigation Partner, James (Josh) Wilson, directly to discuss their legal options.
- For inquiries, call: 877-247-4292 or 212-983-9330 (Ext. 1310)
- For more information, visit: www.faruqilaw.com/TVRD
- Follow updates on social media platforms like LinkedIn and X.
Impact of Clinical Trial Results
The fallout from the Phase 2 REVERT trial arose after the company reported that the study did not meet its predefined goals. The trial aimed to evaluate the safety and pharmacokinetics of TTI-101 in patients with idiopathic pulmonary fibrosis, assessing exploratory outcomes related to lung function.
Preliminary safety data and exploratory efficacy results indicated that changes in Forced Vital Capacity (FVC) were not favorable. Notably, the baseline characteristics of patients were similar across treatment arms, except for the percent predicted FVC, which was lower in the placebo group compared to those receiving TTI-101.
Faruqi & Faruqi's Commitment
Faruqi & Faruqi has been recovering hundreds of millions of dollars for investors since its establishment in 1995. With offices in New York, Pennsylvania, California, and Georgia, the firm's commitment reflects its extensive experience in securities law.
It’s crucial for investors affected by the recent decline in TVRD to understand their rights and the potential for recourse. Faruqi & Faruqi emphasizes the importance of individual discussions regarding specific cases to ensure that all communications are handled confidentially.